Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service ear tubes & middle ear surgery cases in Iowa: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (93 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 245 | 24% |
| 2020 | 2 | 107 | 27% |
| 2021 | 0 | 118 | 30% |
Tympanostomy tubes, tympanoplasty, and ossicular reconstruction: mostly children and working-age adults. Professional codes (what the surgeon bills): CPT 69436, 69631, 69633, 69641.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Iowa; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 11 | 1,050−4.1%/yr | −4.1%/yr | 2.40.7× | 89% | 1,110 in 2030+1%/yr |
| Sleep apnea & airway implants |
Ear tubes & middle ear surgery in every state, and its device makers · Every procedure market in Iowa · Every state · Compare with Ohio
| 2024 |
| 146 |
| 40% |
| 2025 est. | ≈ 100 | – |
| 2026 est. | ≈ 100 | – |
| 2022 | 1 | 150 | 34% |
| 2023 | 1 | 125 | 38% |
| 2024 | 1 | 146 | 40% |
| 2025 from claims | – | 102 82–119 | 41% |
| 2026 forecast | – | 104 82–131 | 40% |
| 2027 forecast | – | 105 78–139 | 40% |
| 2028 forecast | – | 106 75–146 | 41% |
| 2029 forecast | – | 107 73–153 | 41% |
| 2030 forecast | – | 108 71–160 | 42% |
In 2025, 53% hospital outpatient, 47% surgery center.
| −5.4%/yr |
| 0.7 |
| 52% |
| 490 in 2030+0.1%/yr |
| Michigan | 3 | 373−9.8%/yr | −9.8%/yr | 0.4 | 17% | 330 in 2030−2.1%/yr |
| Illinois | 1 | 167−17%/yr | −17%/yr | 0.1 | 14% | 260 in 2030+7.5%/yr |
| Missouri | 1 | 134−17%/yr | −17%/yr | 0.2 | 0% | 240 in 2030+10%/yr |
| 6 |
| 171+55%/yr |
| +55%/yr |
| 0.41.9× |
| 36% |
| 140 in 2030−3.5%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Integra LifeSciences leads with 53% of company spending on these surgeons in 2025, +51 pts on 2024.
In 2025, 2 companies reported engagement with Iowa’s surgeons worth $1,523 in consulting, speaking, meals and travel tied to these products, about $1,523 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 3 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.